

## Citations and Reference Literature: Magnesium

### Citations

1. Abbott RD, Ando F, Masaki KH et al. Dietary magnesium intake and the future risk of coronary heart disease (the Honolulu Heart Program). *Am J Cardiol* 2003;92:665-669.
2. Ford ES, Mokdad AH. Dietary magnesium intake in a national sample of US adults. *J Nutr* 2003;133:2879-2882.
3. Wong ET, Rude RK, Singer FR, Shaw ST Jr. A high prevalence of hypomagnesemia and hypermagnesemia in hospitalized patients. *Am J Clin Pathol* 1983;79:348-352.
4. Fox CH, Ramsomair D, Mahoney MC et al. An investigation of hypomagnesemia among ambulatory urban African Americans. *J Fam Pract* 1999;48:636-639.
5. Al-Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. *Am J Kidney Dis* 1994;24:737-752.
6. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. *Lancet* 1998;352:391-396.
7. Reissinger A, Ludwig M, Utsch B et al. Novel NCCT gene mutations as a cause of Gitelman's syndrome and a systematic review of mutant and polymorphic NCCT alleles. *Kidney Blood Press Res* 2002;25:354-362.
8. Hansen KW, Mosekilde L. [Gitelman syndrome: an overlooked disease with chronic hypomagnesemia and hypokalemia in adults]. *Ugeskr Laeger* 2003;165:1123-1127.
9. Rude RK. Magnesium metabolism and deficiency. *Endocrinol Metab Clin North Am* 1993;22:377-395.
10. Abbott LG, Rude RK. Clinical manifestations of magnesium deficiency. *Miner Electrolyte Metab* 1993;19:314-322.
11. Nadler JL, Buchanan T, Natarajan R et al. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. *Hypertension* 1993;21:1024-1029.
12. Seelig MS. Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). *J Am Coll Nutr* 1994;13:429-446.
13. Koivisto M, Valta P, Hockerstedt K, Lindgren L. Magnesium depletion in chronic terminal liver cirrhosis. *Clin Transplant* 2002;16:325-328.
14. Feillet-Coudray C, Coudray C, Gueux E et al. A new in vitro blood load test using a magnesium stable isotope for assessment of magnesium status. *J Nutr* 2003;133:1220-1223.
15. Haigney MC, Silver B, Tanglao E et al. Noninvasive measurement of tissue magnesium and correlation with cardiac levels. *Circulation* 1995;92:2190-2197.
16. Clark BA, Brown RS. Unsuspected morbid hypermagnesemia in elderly patients. *Am J Nephrol* 1992;12:336-343.
17. Alamoudi OS. Hypomagnesaemia in chronic, stable asthmatics: prevalence, correlation with severity and hospitalization. *Eur Respir J* 2000;16:427-431.
18. Okayama H, Aikawa T, Okayama M et al. Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma. *Jama* 1987;257:1076-1078.
19. Bloch H, Silverman R, Mancherje N et al. Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. *Chest* 1995;107:1576-1581.
20. Ciarallo L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. *Arch Pediatr Adolesc Med* 2000;154:979-983.
21. Lipworth BJ, Clark RA, Fraser CG, McDevitt DG. The biochemical effects of high-dose inhaled salbutamol in patients with asthma. *Eur J Clin Pharmacol* 1989;36:357-360.
22. Rolla G, Bucca C, Bugiani M et al. Hypomagnesemia in chronic obstructive lung disease: effect of therapy. *Magnes Trace Elem* 1990;9:132-136.
23. Meral A, Coker M, Tanac R. Inhalation therapy with magnesium sulfate and salbutamol sulfate in bronchial asthma. *Turk J Pediatr* 1996;38:169-175.
24. Nannini LJ Jr, Pendino JC, Corna RA et al. Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma. *Am J Med* 2000;108:193-197.
25. Rolla G, Bucca C, Brussino L, Colagrande P. Effect of intravenous magnesium infusion on salbutamol-induced bronchodilatation in patients with asthma. *Magnes Res* 1994;7:129-133.
26. Hughes R, Goldkorn A, Masoli M et al. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. *Lancet* 2003;361:2114-2117.
27. Blitz M, Blitz S, Beasley R et al. Inhaled magnesium sulfate in the treatment of acute asthma. *Cochrane Database Syst Rev* 2005:CD003898.
28. Jacobson ED, Faloon WW. Malabsorptive effects of neomycin in commonly used doses. *JAMA* 1961;175:187-190.
29. Roe DA. *Drug-Induced Nutritional Deficiencies*. 2nd ed. Westport, Conn: Avi Publishing; 1985.

## Citations and Reference Literature: Magnesium

30. Kang HS, Kerstan D, Dai L et al. Aminoglycosides inhibit hormone-stimulated  $Mg^{2+}$  uptake in mouse distal convoluted tubule cells. *Can J Physiol Pharmacol* 2000;78:595-602.
31. Kes P, Reiner Z. Symptomatic hypomagnesemia associated with gentamicin therapy. *Magnes Trace Elem* 1990;9:54-60.
32. McLean RM. Magnesium and its therapeutic uses: a review. *Am J Med* 1994;96:63-76.
33. Mazze RI, Cousins MJ. Combined nephrotoxicity of gentamicin and methoxyflurane anaesthesia in man: a case report. *Br J Anaesth* 1973;45:394-398.
34. Valdivieso A, Mardones JM, Loyola MS, Cubillos AM. [Hypomagnesemia associated with hypokalemia, hyponatremia and metabolic alkalosis: possible complication of gentamicin therapy]. *Rev Med Chil* 1992;120:914-919.
35. Parsons PP, Garland HO, Harpur ES, Old S. Acute gentamicin-induced hypercalciuria and hypermagnesiuria in the rat: dose-response relationship and role of renal tubular injury. *Br J Pharmacol* 1997;122:570-576.
36. Alexandridis G, Liberopoulos E, Elisaf M. Aminoglycoside-induced reversible tubular dysfunction. *Pharmacology* 2003;67:118-120.
37. Barr GA, Mazze RI, Cousins MJ, Kosek JC. An animal model for combined methoxyflurane and gentamicin nephrotoxicity. *Br J Anaesth* 1973;45:306-312.
38. Garland HO, Birdsey TJ, Davidge CG et al. Effects of gentamicin, neomycin and tobramycin on renal calcium and magnesium handling in two rat strains. *Clin Exp Pharmacol Physiol* 1994;21:109-115.
39. Keating MJ, Sethi MR, Bodey GP, Samaan NA. Hypocalcemia with hypoparathyroidism and renal tubular dysfunction associated with aminoglycoside therapy. *Cancer* 1977;39:1410-1414.
40. Akbar A, Rees JH, Nyamugunduru G et al. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis. *Acta Paediatr* 1999;88:783-785.
41. Kelnar CJ, Taor WS, Reynolds DJ et al. Hypomagnesaemic hypocalcaemia with hypokalaemia caused by treatment with high dose gentamicin. *Arch Dis Child* 1978;53:817-820.
42. Slayton W, Anstine D, Lakhdar F et al. Tetany in a child with AIDS receiving intravenous tobramycin. *South Med J* 1996;89:1108-1110.
43. Adams JP, Conway SP, Wilson C. Hypomagnesaemic tetany associated with repeated courses of intravenous tobramycin in a patient with cystic fibrosis. *Respir Med* 1998;92:602-604.
44. Hurwitz A. Antacid therapy and drug kinetics. *Clin Pharmacokinet* 1977;2:269-280.
45. Schmidt ME, Kruesi MJ, Elia J et al. Effect of dextroamphetamine and methylphenidate on calcium and magnesium concentration in hyperactive boys. *Psychiatry Res* 1994;54:199-210.
46. Arnold LE. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). *Ann N Y Acad Sci* 2001;931:310-341.
47. Kozielec T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder (ADHD). *Magnes Res* 1997;10:143-148.
48. Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD): positive response to magnesium oral loading test. *Magnes Res* 1997;10:149-156.
49. Mayer J, Doubek M, Vorlicek J. Must we really fear toxicity of conventional amphotericin B in oncological patients? *Support Care Cancer* 1999;7:51-55.
50. Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. *Am J Med* 1984;77:471-474.
51. Mayer J, Doubek M, Doubek J et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. *J Infect Dis* 2002;186:379-388.
52. Doubek M, Mayer J, Horky D. [Safety of long-term administration of conventional amphotericin B in oncology patients]. *Cas Lek Cesk* 2002;141:156-159.
53. Kline S, Larsen TA, Fieber L et al. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. *Clin Infect Dis* 1995;21:1154-1158.
54. Oravcova E, Mistrik M, Sakalova A et al. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. *Chemotherapy* 1995;41:473-476.
55. Gulati M, Bajad S, Singh S et al. Development of liposomal amphotericin B formulation. *J Microencapsul* 1998;15:137-151.
56. Davies SV, Murray JA. Amphotericin B, aminoglycosides, and hypomagnesaemic tetany. *Br Med J Clin Res Ed* 1986;292:1395-1396.
57. Narita M, Itakura O, Ishiguro N, Togashi T. Hypomagnesaemia-associated tetany due to intravenous administration of amphotericin B. *Eur J Pediatr* 1997;156:421-422.

## Citations and Reference Literature: Magnesium

58. Marcus N, Garty BZ. Transient hypoparathyroidism due to amphotericin B-induced hypomagnesemia in a patient with beta-thalassemia. *Ann Pharmacother* 2001;35:1042-1044.
59. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. *Hypertension* 1998;32:260-265.
60. Gaspar AZ, Gasser P, Flammer J. The influence of magnesium on visual field and peripheral vasospasm in glaucoma. *Ophthalmologica* 1995;209:11-13.
61. Goto K, Yasue H, Okumura K et al. Magnesium deficiency detected by intravenous loading test in variant angina pectoris. *Am J Cardiol* 1990;65:709-712.
62. Mervaala EM, Malmberg L, Teravainen TL et al. Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats. *Br J Pharmacol* 1998;123:195-204.
63. Davis WB, Wells SR, Kuller JA, Thorp JM Jr. Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. *Obstet Gynecol Surv* 1997;52:198-201.
64. Snyder SW, Cardwell MS. Neuromuscular blockade with magnesium sulfate and nifedipine. *Am J Obstet Gynecol* 1989;161:35-36.
65. Ben-Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. *Br J Obstet Gynaecol* 1994;101:262-263.
66. Waisman GD, Mayorga LM, Camera MI et al. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? *Am J Obstet Gynecol* 1988;159:308-309.
67. Toffaletti J, Cooper DL, Lobaugh B. The response of parathyroid hormone to specific changes in either ionized calcium, ionized magnesium, or protein-bound calcium in humans. *Metabolism* 1991;40:814-818.
68. Koch Nogueira PC, Hadj-Aissa A, Schell M et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. *Pediatr Nephrol* 1998;12:572-575.
69. Skinner R, Pearson AD, English MW et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. *Br J Cancer* 1998;77:1677-1682.
70. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. *Cancer Treat Rev* 1999;25:47-58.
71. Markmann M, Rothman R, Reichman B et al. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. *J Cancer Res Clin Oncol* 1991;117:89-90.
72. Buckley JE, Clark VL, Meyer TJ, Pearlman NW. Hypomagnesemia after cisplatin combination chemotherapy. *Arch Intern Med* 1984;144:2347-2348.
73. Whang R, Whang DD, Ryan MP. Refractory potassium repletion: a consequence of magnesium deficiency. *Arch Intern Med* 1992;152:40-45.
74. Kibirige MS, Morris-Jones PH, Addison GM. Prevention of cisplatin-induced hypomagnesemia. *Pediatr Hematol Oncol* 1988;5:1-6.
75. Rodriguez M, Solanki DL, Whang R. Refractory potassium repletion due to cisplatin-induced magnesium depletion. *Arch Intern Med* 1989;149:2592-2594.
76. Van de Loosdrecht AA, Gietema JA, van der Graaf WT. Seizures in a patient with disseminated testicular cancer due to cisplatin-induced hypomagnesaemia. *Acta Oncol* 2000;39:239-240.
77. Roe DA. *Drug-Induced Nutritional Deficiencies*. 2nd ed. Westport, Conn: Avi Publishing; 1985.
78. Simeckova A, Neradilova M, Reisenauer R. Effect of prednisolone on the rat bone calcium, phosphorus and magnesium concentration. *Physiol Bohemoslov* 1985;34:155-160.
79. Atkinson SA, Halton JM, Bradley C et al. Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition. *Int J Cancer Suppl* 1998;11:35-39.
80. Cashman KD, Flynn A. Optimal nutrition: calcium, magnesium and phosphorus. *Proc Nutr Soc* 1999;58:477-487.
81. Naggar VF, Khalil SA, Gouda MW. Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans. *J Pharm Sci* 1978;67:1029-1030.
82. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. *J Neurol* 1999;246:339-346.
83. Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporine neurotoxicity and hypomagnesaemia. *Lancet* 1984;324:1116-1120.
84. June CH, Thompson CB, Kennedy MS et al. Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation. *Transplantation* 1985;39:620-624.
85. June CH, Thompson CB, Kennedy MS et al. Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients. *Transplantation* 1986;41:47-51.
86. Barton CH, Vaziri ND, Martin DC et al. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. *Am J Med* 1987;83:693-699.

## Citations and Reference Literature: Magnesium

87. Rahman MA, Ing TS. Cyclosporine and magnesium metabolism. *J Lab Clin Med* 1989;114:213-214.
88. Kaiser W, Biesenbach G, Kramer E, Zazgornik J. Magnesium after renal transplantation: comparison between cyclosporine A and conventional immunosuppression. *Adv Exp Med Biol* 1989;252:297-302.
89. Nozue T, Kobayashi A, Kodama T et al. Pathogenesis of cyclosporine-induced hypomagnesemia. *J Pediatr* 1992;120:638-640.
90. Vannini SD, Mazzola BL, Rodoni L et al. Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. *Transpl Int* 1999;12:244-249.
91. Pere AK, Lindgren L, Tuomainen P et al. Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity. *Kidney Int* 2000;58:2462-2472.
92. Derici U, Arinsoy T, Sindel S et al. Cyclosporine-A induced neurotoxicity after renal transplantation. *Acta Neurol Belg* 2001;101:124-127.
93. Miura K, Nakatani T, Asai T et al. Role of hypomagnesemia in chronic cyclosporine nephropathy. *Transplantation* 2002;73:340-347.
94. Thakur V, Kumar R, Dhawan IK. Correlation between serum magnesium and blood cyclosporine A concentrations in renal transplant recipients. *Ann Clin Biochem* 2002;39:70-72.
95. Pere AK, Krogerus L, Mervaala EM et al. Beneficial effects of dietary magnesium and potassium on cardiac and renal morphologic features in cyclosporin A-induced damage in spontaneously hypertensive rats. *Surgery* 2000;128:67-75.
96. Asai T, Nakatani T, Yamanaka S et al. Magnesium supplementation prevents experimental chronic cyclosporine A nephrotoxicity via renin-angiotensin system independent mechanism. *Transplantation* 2002;74:784-791.
97. Asai T, Nakatani T, Tamada S et al. Activation of transcription factors AP-1 and NF-kappaB in chronic cyclosporine A nephrotoxicity: role in beneficial effects of magnesium supplementation. *Transplantation* 2003;75:1040-1044.
98. Ozkaya O, Kalman S, Bakkaloglu S et al. Cyclosporine-associated facial paralysis in a child with renal transplant. *Pediatr Nephrol* 2002;17:544-546.
99. Al-Rasheed AK, Blaser SI, Minassian BA et al. Cyclosporine A neurotoxicity in a patient with idiopathic renal magnesium wasting. *Pediatr Neurol* 2000;23:353-356.
100. Kupfer S, Kosovsky JD. Effects of cardiac glycosides on renal tubular transport of calcium, magnesium, inorganic phosphate, and glucose in the dog. *J Clin Invest* 1965;44:1132-1143.
101. Whang R, Oei TO, Watanabe A. Frequency of hypomagnesemia in hospitalized patients receiving digitalis. *Arch Intern Med* 1985;145:655-656.
102. Toffaletti J. Electrolytes, divalent cations, and blood gases (magnesium). *Analyt Chem* 1991;63:192R-194R.
103. Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, Carrara GC. Magnesium and cardiovascular drugs: interactions and therapeutic role. *Ann Ital Med Int* 1999;14:40-45.
104. Whang R, Flink EB, Dyckner T et al. Magnesium depletion as a cause of refractory potassium repletion. *Arch Intern Med* 1985;145:1686-1689.
105. Seelig M. Cardiovascular consequences of magnesium deficiency and loss: pathogenesis, prevalence and manifestations: magnesium and chloride loss in refractory potassium repletion. *Am J Cardiol* 1989;63:4G-21G.
106. Cohen L, Kitzes R. Magnesium sulfate and digitalis-toxic arrhythmias. *JAMA* 1983;249:2808-2810.
107. Landauer JA. Magnesium deficiency and digitalis toxicity. *JAMA* 1984;251:730.
108. Lewis R, Durnin C, McLay J et al. Magnesium deficiency may be an important determinant of ventricular ectopy in digitalised patients with chronic atrial fibrillation. *Br J Clin Pharmacol* 1991;31:200-203.
109. Brown DD, Juhl RP. Decreased bioavailability of digoxin due to antacids and kaolin-pectin. *N Engl J Med* 1976;295:1034-1037.
110. Greenblatt DJ, Duhme DW, Koch-Weser J, Smith TW. Evaluation of digoxin bioavailability in single-dose studies. *N Engl J Med* 1973;289:651-654.
111. McElnay JC, Harron DW, D'Arcy PF, Eagle MR. Interaction of digoxin with antacid constituents. *Br Med J* 1978;1:1554.
112. D'Arcy PF, McElnay JC. Drug-antacid interactions: assessment of clinical importance. *Drug Intell Clin Pharm* 1987;21:607-617.
113. Kinlay S, Buckley NA. Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity. *J Toxicol Clin Toxicol* 1995;33:55-59.
114. Davies DL, Lant AF, Millard NR et al. Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide. *Clin Pharmacol Ther* 1974;15:141-155.
115. Abrams J. Intramuscular bumetanide and furosemide in congestive heart failure. *J Clin Pharmacol* 1981;21:673-679.
116. Ryan MP, Devane J, Ryan MF, Counihan TB. Effects of diuretics on the renal handling of magnesium. *Drugs* 1984;28 Suppl 1:167-181.
117. Ryan MP. Magnesium and potassium-sparing diuretics. *Magnesium* 1986;5:282-292.

## Citations and Reference Literature: Magnesium

118. Kroenke K, Wood DR, Hanley JF. The value of serum magnesium determination in hypertensive patients receiving diuretics. *Arch Intern Med* 1987;147:1553-1556.
119. Martin BJ, Milligan K. Diuretic-associated hypomagnesemia in the elderly. *Arch Intern Med* 1987;147:1768-1771.
120. Leary WP, Reyes AJ, Wynne RD, van der Byl K. Renal excretory actions of furosemide, of hydrochlorothiazide and of the vasodilator flosequinan in healthy subjects. *J Int Med Res* 1990;18:120-141.
121. Quamme GA. Renal magnesium handling: new insights in understanding old problems. *Kidney Int* 1997;52:1180-1195.
122. Dai LJ, Friedman PA, Quamme GA. Cellular mechanisms of chlorothiazide and cellular potassium depletion on Mg<sup>2+</sup> uptake in mouse distal convoluted tubule cells. *Kidney Int* 1997;51:1008-1017.
123. Schwinger RH, Erdmann E. Heart failure and electrolyte disturbances. *Methods Find Exp Clin Pharmacol* 1992;14:315-325.
124. Oladapo OO, Falase AO. Serum and urinary magnesium during treatment of patients with chronic congestive heart failure. *Afr J Med Med Sci* 2000;29:301-303.
125. Oladapo OO, Falase AO. Congestive heart failure and ventricular arrhythmias in relation to serum magnesium. *Afr J Med Med Sci* 2000;29:265-268.
126. Iseri LT, Freed J, Bures AR. Magnesium deficiency and cardiac disorders. *Am J Med* 1975;58:837-846.
127. Dyckner T, Wester PO. Potassium/magnesium depletion in patients with cardiovascular disease. *Am J Med* 1987;82:11-17.
128. Ruml LA, Pak CY. Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss. *Am J Kidney Dis* 1999;34:107-113.
129. Dorup I. Magnesium and potassium deficiency: its diagnosis, occurrence and treatment in diuretic therapy and its consequences for growth, protein synthesis and growth factors. *Acta Physiol Scand Suppl* 1994;618:1-55.
130. Douban S, Brodsky MA, Whang DD, Whang R. Significance of magnesium in congestive heart failure. *Am Heart J* 1996;132:664-671.
131. Cohen N, Almozino-Sarafian D, Zaidenstein R et al. Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation. *Heart* 2003;89:411-416.
132. Dorup I, Skajaa K, Thybo NK. [Oral magnesium supplementation to patients receiving diuretics: normalization of magnesium, potassium and sodium, and potassium pumps in the skeletal muscles]. *Ugeskr Laeger* 1994;156:4007-4010, 4013.
133. Ruml LA, Gonzalez G, Taylor R et al. Effect of varying doses of potassium-magnesium citrate on thiazide-induced hypokalemia and magnesium loss. *Am J Ther* 1999;6:45-50.
134. Cohen N, Alon I, Almozino-Sarafian D et al. Metabolic and clinical effects of oral magnesium supplementation in furosemide-treated patients with severe congestive heart failure. *Clin Cardiol* 2000;23:433-436.
135. Hollenberg NK, Mickiewicz C. Hyperkalemia in diabetes mellitus: effect of a triamterene-hydrochlorothiazide combination. *Arch Intern Med* 1989;149:1327-1330.
136. Seelig MS. Increased need for magnesium with the use of combined oestrogen and calcium for osteoporosis treatment. *Magnes Res* 1990;3:197-215.
137. Blum M, Kitai E, Ariel Y et al. [Oral contraceptive lowers serum magnesium]. *Harefuah* 1991;121:363-364.
138. Seelig MS. Interrelationship of magnesium and estrogen in cardiovascular and bone disorders, eclampsia, migraine and premenstrual syndrome. *J Am Coll Nutr* 1993;12:442-458.
139. Tyrer LB. Nutrition and the pill. *J Reprod Med* 1984;29:547-550.
140. Stanton MF, Lowenstein FW. Serum magnesium in women during pregnancy, while taking contraceptives, and after menopause. *J Am Coll Nutr* 1987;6:313-319.
141. Muneyyirci-Delale O, Nacharaju VL, Dalloul M et al. Serum ionized magnesium and calcium in women after menopause: inverse relation of estrogen with ionized magnesium. *Fertil Steril* 1999;71:869-872.
142. Olatunbosun DA, Adeniyi FA, Adadevoh BK. Effect of oral contraceptives on serum magnesium levels. *Int J Fertil* 1974;19:224-226.
143. Hameed A, Majeed T, Rauf S et al. Effect of oral and injectable contraceptives on serum calcium, magnesium and phosphorus in women. *J Ayub Med Coll Abbottabad* 2001;13:24-25.
144. Herzberg M, Lusky A, Blonder J, Frenkel Y. The effect of estrogen replacement therapy on zinc in serum and urine. *Obstet Gynecol* 1996;87:1035-1040.
145. Abraham GE, Lubran MM. Serum and red cell magnesium levels in patients with premenstrual tension. *Am J Clin Nutr* 1981;34:2364-2366.
146. Sherwood RA, Rocks BF, Stewart A, Saxton RS. Magnesium and the premenstrual syndrome. *Ann Clin Biochem* 1986;23(Pt 6): 667-670.

## Citations and Reference Literature: Magnesium

147. Nicholas A. Traitement du syndrome pre-menstruel et de la dysmenorrhée par l'ion magnésium. In: Durlach J, ed. First International Symposium on Magnesium Deficit in Human Pathology. Paris: Springer-Verlag; 1973:261-263.
148. Facchinetti F, Borella P, Sances G et al. Oral magnesium successfully relieves premenstrual mood changes. *Obstet Gynecol* 1991;78:177-181.
149. Koinig H, Wallner T, Marhofer P et al. Magnesium sulfate reduces intra- and postoperative analgesic requirements. *Anesth Analg* 1998;87:206-210.
150. Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. *Am J Med* 1989;87:76S-81S.
151. Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs: an update. *Clin Pharmacokinet* 1990;18:210-219.
152. Shimada J, Shiba K, Oguma T et al. Effect of antacid on absorption of the quinolone lomefloxacin. *Antimicrob Agents Chemother* 1992;36:1219-1224.
153. Shiba K, Sakamoto M, Nakazawa Y, Sakai O. Effects of antacid on absorption and excretion of new quinolones. *Drugs* 1995;49 Suppl 2:360-361.
154. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. *Clin Pharmacokinet* 1997;32:101-119.
155. Grasela TH Jr, Schentag JJ, Sedman AJ et al. Inhibition of enoxacin absorption by antacids or ranitidine. *Antimicrob Agents Chemother* 1989;33:615-617.
156. Hoffken G, Lode H., Wiley R. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. *Rev Infect Dis* 1988;10:S138-S139.
157. Nix DE, Watson WA, Lener ME et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. *Clin Pharmacol Ther* 1989;46:700-705.
158. Kara M, Hasinoff BB, McKay DW, Campbell NR. Clinical and chemical interactions between iron preparations and ciprofloxacin. *Br J Clin Pharmacol* 1991;31:257-261.
159. Campbell NR, Hasinoff BB. Iron supplements: a common cause of drug interactions. *Br J Clin Pharmacol* 1991;31:251-255.
160. Brouwers JR. Drug interactions with quinolone antibacterials. *Drug Saf* 1992;7:268-281.
161. Shiba K, Sakai O, Shimada J et al. Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. *Antimicrob Agents Chemother* 1992;36:2270-2274.
162. Teixeira MH, Vilas-Boas LF, Gil VM, Teixeira F. Complexes of ciprofloxacin with metal ions contained in antacid drugs. *J Chemother* 1995;7:126-132.
163. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. *J Antimicrob Chemother* 1996;37 Suppl A:41-55.
164. Teng R, Dogolo LC, Willavize SA et al. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. *J Antimicrob Chemother* 1997;39 Suppl B:93-97.
165. Balfour JA, Wiseman LR. Moxifloxacin. *Drugs* 1999;57:363-373; discussion 374.
166. Li RC, Lo KN, Lam JS, Lau PY. Effects of order of magnesium exposure on the postantibiotic effect and bactericidal activity of ciprofloxacin. *J Chemother* 1999;11:243-247.
167. Hoffken G, Borner K, Glatzel PD et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. *Eur J Clin Microbiol* 1985;4:345.
168. Schentag JJ, Watson WA, Nix DE et al. Time-dependent interactions between antacids and quinolone antibiotics. *Clin Pharmacol Ther* 1988;43:135.
169. Noyes M, Polk RE. Norfloxacin and absorption of magnesium-aluminum. *Ann Intern Med* 1988;109:168-169.
170. Nix DE, Wilton JH, Ronald B et al. Inhibition of norfloxacin absorption by antacids. *Antimicrob Agents Chemother* 1990;34:432-435.
171. Roush MK, Dupuis RE. Significance of the ciprofloxacin-antacid interaction. *DICP* 1991;25:473-475.
172. Lomaestro BM, Bailie GR. Quinolone-cation interactions: a review. *DICP* 1991;25:1249-1258.
173. Nightingale CH. Pharmacokinetic considerations in quinolone therapy. *Pharmacotherapy* 1993;13:34S-38S.
174. Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H<sub>2</sub> antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. *Clin Pharmacokinet* 2001;40 Suppl 1:39-48.
175. Noormohamed FH, Youle MS, Tang B et al. Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients. *Antivir Ther* 1996;1:172-179.
176. Huycke MM, Naguib MT, Stroemmel MM et al. A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection. *Antimicrob Agents Chemother* 2000;44:2143-2148.

## Citations and Reference Literature: Magnesium

177. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. *Clin Infect Dis* 2002;34:1337-1341.
178. Gearhart MO, Sorg TB. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. *Ann Pharmacother* 1993;27:285-289.
179. Salmeron J, Manson JE, Stampfer MJ et al. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. *JAMA* 1997;277:472-477.
180. Paolisso G, Scheen A, D'Onofrio F, Lefebvre P. Magnesium and glucose homeostasis. *Diabetologia* 1990;33:511-514.
181. Magnesium supplementation in the treatment of diabetes. American Diabetes Association. *Diabetes Care* 1992;15:1065-1067.
182. De Valk HW. Magnesium in diabetes mellitus. *Neth J Med* 1999;54:139-146.
183. Paolisso G, Sgambato S, Pizza G et al. Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. *Diabetes Care* 1989;12:265-269.
184. Lima Mde L, Cruz T, Pousada JC et al. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care* 1998;21:682-686.
185. Eibl NL, Kopp HP, Nowak HR et al. Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy. *Diabetes Care* 1995;18:188-192.
186. Johnsen SP, Husted SE, Ravn HB et al. [Magnesium supplementation to patients with type II diabetes]. *Ugeskr Laeger* 1999;161:945-948.
187. Paolisso G, Sgambato S, Gambardella A et al. Daily magnesium supplements improve glucose handling in elderly subjects. *Am J Clin Nutr* 1992;55:1161-1167.
188. Smellie WS, O'Reilly DS, Martin BJ, Santamaria J. Magnesium replacement and glucose tolerance in elderly subjects. *Am J Clin Nutr* 1993;57:594-596.
189. Sjogren A, Floren CH, Nilsson A. Oral administration of magnesium hydroxide to subjects with insulin-dependent diabetes mellitus: effects on magnesium and potassium levels and on insulin requirements. *Magnesium* 1988;7:117-122.
190. De Valk HW, Verkaarik R, van Rijn HJ et al. Oral magnesium supplementation in insulin-requiring type 2 diabetic patients. *Diabet Med* 1998;15:503-507.
191. McNair P, Christiansen C, Madsbad S et al. Hypomagnesemia, a risk factor in diabetic retinopathy. *Diabetes* 1978;27:1075-1077.
192. De Valk HW, Hardus PL, van Rijn HJ, Erkelens DW. Plasma magnesium concentration and progression of retinopathy. *Diabetes Care* 1999;22:864-865.
193. Birch NJ, Hughes MS. Lithium and magnesium-dependent processes in glucose metabolism. *Physiologie* 1989;26:25-29.
194. Ramasamy R, de Freitas DM. Competition between  $\text{Li}^+$  and  $\text{Mg}^{2+}$  for ATP in human erythrocytes: a  $^{31}\text{P}$  NMR and optical spectroscopy study. *FEBS Lett* 1989;244:223-226.
195. Padiyar GS, Seshadri TP. Metal-nucleotide interactions: crystal structures of alkali ( $\text{Li}^+$ ,  $\text{Na}^+$ ,  $\text{K}^+$ ) and alkaline earth ( $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ ) metal complexes of adenosine 2'-monophosphate. *J Biomol Struct Dyn* 1998;15:803-821.
196. Nielsen J. Magnesium-lithium studies. 1. Serum and erythrocyte magnesium in patients with manic states during lithium treatment. *Acta Psychiatr Scand* 1964;40:190-196.
197. Nielsen J. Magnesium-lithium studies. 2. The effect of lithium on serum magnesium in rabbits. *Acta Psychiatr Scand* 1964;40:197-202.
198. Herzberg L, Herzeberg B. Mood change and magnesium: a possible interaction between magnesium and lithium? *J Nerv Ment Dis* 1977;165:423-426.
199. Goode DL, Newton DW, Ueda CT et al. Effect of antacid on the bioavailability of lithium carbonate. *Clin Pharm* 1984;3:284-287.
200. Holt GA. Food and Drug Interactions. Chicago: Precept Press; 1998.
201. Garris RE, Kirkwood CF. Misoprostol: a prostaglandin  $\text{E}_1$  analogue. *Clin Pharm* 1989;8:627-644.
202. Morris R, Giesecke AH. Potentiation of muscle relaxants by magnesium sulphate in toxemia of pregnancy. *South Med J* 1968;61:25.
203. Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular blocking agents. *Anesthesiology* 1970;32:23-27.
204. Sinatra RS, Philip BK, Naulty JS, Ostheimer GW. Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulfate. *Anesth Analg* 1985;64:1220-1222.
205. Baraka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. *Anesthesiology* 1987;67:806-808.
206. Ip-Yam C, Allsop E. Abnormal response to suxamethonium in a patient receiving magnesium therapy. *Anaesthesia* 1994;49:355-356.

## Citations and Reference Literature: Magnesium

207. Gaiser RR, Seem EH. Use of rocuronium in a pregnant patient with an open eye injury, receiving magnesium medication, for preterm labour. *Br J Anaesth* 1996;77:669-671.
208. Feldman S, Karalliedde L. Drug interactions with neuromuscular blockers. *Drug Saf* 1996;15:261-273.
209. Osman MA, Patel RB, Schuna A et al. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate. *Clin Pharmacol Ther* 1983;33:465-470.
210. Seelig MS. Auto-immune complications of d-penicillamine: a possible result of zinc and magnesium depletion and of pyridoxine inactivation. *J Am Coll Nutr* 1982;1:207-214.
211. Zhang Y, Li Z, Pilch DS, Leibowitz MJ. Pentamidine inhibits catalytic activity of group I intron Ca.LSU by altering RNA folding. *Nucleic Acids Res* 2002;30:2961-2971.
212. Cortes E, Jufresa J, Falco V, Ribera E. [Hypocalcemia and hypomagnesemia associated with the treatment with pentamidine in 2 patients with HIV infection]. *Med Clin (Barc)* 1996;106:717.
213. Otsuka M, Kanamori H, Sasaki S et al. Torsades de pointes complicating pentamidine therapy of *Pneumocystis carinii* pneumonia in acute myelogenous leukemia. *Intern Med* 1997;36:705-708.
214. Po SS, Wang DW, Yang IC et al. Modulation of HERG potassium channels by extracellular magnesium and quinidine. *J Cardiovasc Pharmacol* 1999;33:181-185.
215. Sadowski DC. Drug interactions with antacids: mechanisms and clinical significance. *Drug Saf* 1994;11:395-407.
216. Bunchman TE, Wood EG, Schenck MH et al. Pretreatment of formula with sodium polystyrene sulfonate to reduce dietary potassium intake. *Pediatr Nephrol* 1991;5:29-32.
217. Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. *Br J Clin Pharmacol* 1997;43:269-272.
218. Stark G, Schwarzl I, Heiden U et al. Magnesium abolishes inadequate kinetics of frequency adaptation of the Q-aT interval in the presence of sotalol. *Cardiovasc Res* 1997;35:43-51.
219. Frick M, Darpo B, Ostergren J, Rosenqvist M. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. *Eur Heart J* 2000;21:1177-1185.
220. Forlani S, De Paulis R, de Notaris S et al. Combination of sotalol and magnesium prevents atrial fibrillation after coronary artery bypass grafting. *Ann Thorac Surg* 2002;74:720-725; discussion 725-726.
221. Arstall MA, Hii JT, Lehman RG, Horowitz JD. Sotalol-induced torsade de pointes: management with magnesium infusion. *Postgrad Med J* 1992;68:289-290.
222. Sasse M, Paul T, Bergmann P, Kallfelz HC. Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate. *Pacing Clin Electrophysiol* 1998;21:1164-1166.
223. Lehto P, Laine K, Kivisto KT, Neuvonen PJ. The effect of pH on the in-vitro dissolution of three second-generation sulphonylurea preparations: mechanism of antacid-sulphonylurea interaction. *J Pharm Pharmacol* 1996;48:899-901.
224. Kivisto KT, Neuvonen PJ. Enhancement of absorption and effect of glipizide by magnesium hydroxide. *Clin Pharmacol Ther* 1991;49:39-43.
225. Neuvonen PJ, Kivisto KT. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. *Br J Clin Pharmacol* 1991;32:215-220.
226. Neuvonen PJ, Kivisto KT. Enhancement of drug absorption by antacids: an unrecognised drug interaction. *Clin Pharmacokinet* 1994;27:120-128.
227. McBain AM, Brown IR, Menzies DG, Campbell IW. Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes. *J Clin Pathol* 1988;41:933-935.
228. McCarty MF. Exploiting complementary therapeutic strategies for the treatment of type II diabetes and prevention of its complications. *Med Hypotheses* 1997;49:143-152.
229. Neuvonen PJ. Interactions with the absorption of tetracyclines. *Drugs* 1976;11:45-54.
230. Berthon G, Brion M, Lambs L. Metal ion-tetracycline interactions in biological fluids. 2. Potentiometric study of magnesium complexes with tetracycline, oxytetracycline, doxycycline, and minocycline, and discussion of their possible influence on the bioavailability of these antibiotics in blood plasma. *J Inorg Biochem* 1983;19:1-18.
231. Lambs L, Brion M, Berthon G. Metal ion-tetracycline interactions in biological fluids. Part 3. Formation of mixed-metal ternary complexes of tetracycline, oxytetracycline, doxycycline and minocycline with calcium and magnesium, and their involvement in the bioavailability of these antibiotics in blood plasma. *Agents Actions* 1984;14:743-750.
232. Brion M, Lambs L, Berthon G. Metal ion-tetracycline interactions in biological fluids. Part 5. Formation of zinc complexes with tetracycline and some of its derivatives and assessment of their biological significance. *Agents Actions* 1985;17:229-242.
233. Lambs L, Venturini M, Decock-Le Reverend B et al. Metal ion-tetracycline interactions in biological fluids. Part 8. Potentiometric and spectroscopic studies on the formation of Ca(II) and Mg(II) complexes with 4-dedimethylamino-tetracycline and 6-desoxy-6-demethyl-tetracycline. *J Inorg Biochem* 1988;33:193-210.

## Citations and Reference Literature: Magnesium

234. Machado FC, Demicheli C, Garnier-Suillerot A, Beraldo H. Metal complexes of anhydrotetracycline. 2. Absorption and circular dichroism study of Mg(II), Al(III), and Fe(III) complexes: possible influence of the Mg(II) complex on the toxic side effects of tetracycline. *J Inorg Biochem* 1995;60:163-173.
235. Hines Burnham T et al. *Drug Facts and Comparisons*. St Louis: Facts and Comparisons; 2000:1286.
236. Sifton DW, ed. *Physicians' Desk Reference*. Montvale, NJ: Medical Economics Company; 2000:1535-1537.
237. Rayssiguier Y. Hypomagnesemia resulting from adrenaline infusion in ewes: its relation to lipolysis. *Horm Metab Res* 1977;9:309-314.
238. Smith SR, Gove I, Kendall MJ. Beta agonists and potassium. *Lancet* 1985;1:1394-1395.
239. Flack JM, Ryder KW, Strickland D, Whang R. Metabolic correlates of theophylline therapy: a concentration-related phenomenon. *Ann Pharmacother* 1994;28:175-179.
240. Hall KW, Dobson KE, Dalton JG et al. Metabolic abnormalities associated with intentional theophylline overdose. *Ann Intern Med* 1984;101:457-462.
241. Flink EB. Magnesium deficiency in human subjects: a personal historical perspective. *J Am Coll Nutr* 1985;4:17-31.
242. Hagley MT, Traeger SM, Schuckman H. Pronounced metabolic response to modest theophylline overdose. *Ann Pharmacother* 1994;28:195-196.
243. Iannello S, Spina M, Leotta P et al. Hypomagnesemia and smooth muscle contractility: diffuse esophageal spasm in an old female patient. *Miner Electrolyte Metab* 1998;24:348-356.
244. Chevalier B, le Heuzey JY, Colombel B et al. [Ventricular tachycardia during theophylline overdose: apropos of a case of reduction by magnesium chloride]. *Arch Mal Coeur Vaiss* 1990;83:569-573.
245. Chugh K. Acute asthma in emergency room. *Indian J Pediatr* 2003;70 Suppl 1:S28-S33.
246. Bighley LD, Spivey RJ. Chelates of dicumarol. I. Preparation and structure identification of magnesium chelate. *J Pharm Sci* 1977;66:1124-1127.
247. Pinto JT. The pharmacokinetic and pharmacodynamic interactions of foods and drugs. *Top Clin Nutr* 1991;6:14-33.
248. McElnay JC, Harron DW, D'Arcy PF, Collier PS. The interaction of warfarin with antacid constituents in the gut. *Experientia* 1979;35:1359-1360.
249. Ambre JJ, Fischer LJ. Effect of coadministration of aluminum and magnesium hydroxides on absorption of anticoagulants in man. *Clin Pharmacol Ther* 1973;14:231-237.
250. Van der Giesen WF, Wilting J. Analysis of the mechanism of the magnesium effect on the warfarin-albumin interaction. *Biochem Pharmacol* 1984;33:1679-1681.
251. Perez Gallardo L. In vitro effect of  $\text{Cl}_2\text{Ca}$  and  $\text{Cl}_2\text{Mg}$  on warfarin-human serum albumin (HSA) binding. *Magnes Res* 1999;12:43-48.
252. O'Keeffe S, Grimes H, Finn J et al. Effect of captopril therapy on lymphocyte potassium and magnesium concentrations in patients with congestive heart failure. *Cardiology* 1992;80:100-105.
253. Lavin F, O'Keeffe S, Grimes H et al. Effect of prolonged nifedipine or captopril therapy on lymphocyte magnesium and potassium levels in hypertension. *Cardiology* 1993;82:405-408.
254. Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. *Dig Dis Sci* 1985;30:477-482.
255. Niebergall PJ, Hussar DA, Cressman WA et al. Metal binding tendencies of various antibiotics. *J Pharm Pharmacol* 1966;18:729-738.
256. Zhu M, Nix DE, Adam RD et al. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. *Pharmacotherapy* 2001;21:891-897.
257. Schindler AM. Isolated neonatal hypomagnesaemia associated with maternal overuse of stool softener. *Lancet* 1984;2:822.
258. Raab W. Cardiotoxic effects of emotional, socioeconomic, and environmental stresses. In: Bajusz E, Rona G, eds. *Myocardiology*. Vol I. Baltimore: University Park Press; 1970:707-713.
259. Ryzen E, Servis KL, Rude RK. Effect of intravenous epinephrine on serum magnesium and free intracellular red blood cell magnesium concentrations measured by nuclear magnetic resonance. *J Am Coll Nutr* 1990;9:114-119.
260. Herbaczynska-Cedro K, Gajkowska B. Effect of magnesium on myocardial damage induced by epinephrine: ultrastructural and cytochemical study. *Cardioscience* 1992;3:197-203.
261. Delhumeau A, Granry JC, Monrigal JP, Costerousse F. [Indications for the use of magnesium in anesthesia and intensive care]. *Ann Fr Anesth Reanim* 1995;14:406-416.
262. Bachmann KA, Sullivan TJ, Jauregui L et al. Drug interactions of H<sub>2</sub>-receptor antagonists. *Scand J Gastroenterol Suppl* 1994;206:14-19.

## Citations and Reference Literature: Magnesium

263. Anti-infectives, antimalarial preparations, 4-aminoquinoline compounds. In: Olin B, ed. Facts and Comparisons Drug Information. St Louis: Facts and Comparisons; 1993:1913-1916.
264. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. *Int J Tuberc Lung Dis* 1999;3:703-710.
265. Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. *Br J Clin Pharmacol* 1996;41:513-516.
266. Mannisto P. The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers. *Int J Clin Pharmacol Biopharm* 1978;16:223-228.
267. Naggar VF, Khalil SA. Effect of magnesium trisilicate on nitrofurantoin absorption. *Clin Pharmacol Ther* 1979;25:857-863.
268. Soci MM, Parrott EL. Influence of viscosity on absorption from nitrofurantoin suspensions. *J Pharm Sci* 1980;69:403-406.
269. Devane J, Ryan MP. The effects of amiloride and triamterene on urinary magnesium excretion in conscious saline-loaded rats. *Br J Pharmacol* 1981;72:285-289.
270. Ryder KM, Shorr RI, Bush AJ et al. Magnesium intake from food and supplements is associated with bone mineral density in healthy older white subjects. *J Am Geriatr Soc* 2005;53:1875-1880.
271. Norman DA, Fordtran JS, Brinkley LJ et al. Jejunal and ileal adaptation to alterations in dietary calcium: changes in calcium and magnesium absorption and pathogenetic role of parathyroid hormone and 1,25-dihydroxyvitamin D. *J Clin Invest* 1981;67:1599-1603.
272. Lewis NM, Marcus MS, Behling AR, Greger JL. Calcium supplements and milk: effects on acid-base balance and on retention of calcium, magnesium, and phosphorus. *Am J Clin Nutr* 1989;49:527-533.
273. Andon MB, Ilich JZ, Tzagournis MA, Matkovic V. Magnesium balance in adolescent females consuming a low- or high-calcium diet. *Am J Clin Nutr* 1996;63:950-953.
274. Disch G, Classen HG, Haubold W, Spatling L. Interactions between magnesium and iron: in vitro studies. *Arzneimittelforschung* 1994;44:647-650.
275. Newhouse IJ, Clement DB, Lai C. Effects of iron supplementation and discontinuation on serum copper, zinc, calcium, and magnesium levels in women. *Med Sci Sports Exerc* 1993;25:562-571.
276. Disch G, Classen HG, Spatling L et al. Therapeutic availability of iron administered orally as the ferrous gluconate together with magnesium-l-aspartate hydrochloride. *Arzneimittelforschung* 1996;46:302-306.
277. Spencer H, Norris C, Williams D. Inhibitory effects of zinc on magnesium balance and magnesium absorption in man. *J Am Coll Nutr* 1994;13:479-484.
278. Lumme JA, Jounela AJ. The effect of potassium and potassium plus magnesium supplementation on ventricular extrasystoles in mild hypertensives treated with hydrochlorothiazide. *Int J Cardiol* 1989;25:93-97.
279. Majoor CL, de Vries LA. [The development of cardiac beriberi with polyneuritis after protracted use of large amounts of magnesium trisilicate: an unpublished observation by Dr. J. G. G. Borst]. *Ned Tijdschr Geneesk* 1980;124:1411-1416.

## Reference Literature

- [No authors given.] Magnesium supplementation in the treatment of diabetes: American Diabetes Association. *Diabetes Care* 1992;15(8):1065-1067.
- Abbott LG, Rude RK. Clinical manifestations of magnesium deficiency. *Miner Electrolyte Metab* 1993;19(4-5):314-322. (Review)
- Abbott RD, Ando F, Masaki KH, et al. Dietary magnesium intake and the future risk of coronary heart disease (the Honolulu Heart Program). *Am J Cardiol* 2003;92(6):665-669.
- Abraham AS, Brooks BA, Grafstein Y, et al. Effects of hydrochlorothiazide, diltiazem and enalapril on mononuclear cell sodium and magnesium levels in systemic hypertension. *Am J Cardiol* 1991;68:1357-1361.
- Akbar A, Rees JH, Nyamugunduru G, et al. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis. *Acta Paediatr* 1999;88(7):783-785.
- al-Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. *Am J Kidney Dis* 1994;24(5):737-752. (Review)
- Altura BT, Wilimzig C, Trnovec T, et al. Comparative effects of a Mg-enriched diet and different orally administered magnesium oxide preparations on ionized Mg, Mg metabolism and electrolytes in serum of human volunteers. *J Am Coll Nutr* 1994;13(5):447-454.
- Amighi J, Sabeti S, Schlager O, et al. Low serum magnesium predicts neurological events in patients with advanced atherosclerosis. *Stroke* 2004;35(1):22-27.
- Angus RM, Sambrook PN, Pocock NA, et al. Dietary intake and bone mineral density. *Bone Miner* 1988;4(3):265-277.
- Ariceta G, Rodriguez-Soriano J, Vallo A, et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. *Med Pediatr Oncol* 1997;28(1):35-40.

## Citations and Reference Literature: Magnesium

- Attias J, Weisz G, Almog S, et al. Oral magnesium intake reduces permanent hearing loss induced by noise exposure. *Am J Otolaryngol* 1994;15(1):26-32.
- Barros LF, Chagas AC, da Luz PL, et al. Magnesium treatment of acute myocardial infarction: effects on necrosis in an occlusion/reperfusion dog model. *Intl J Cardiol* 1995;48(1):3-9.
- Bianchetti MG, Kanaka C, Ridolfi-Luthy A, et al. Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin. *Pediatr Nephrol* 1990;4(3):219-222.
- Blitz M, Blitz S, Hughes R, et al. Aerosolized magnesium sulfate for acute asthma: a systematic review. *Chest* 2005;128(1):337-344. (Review)
- Bo S, Durazzo M, Guidi S, et al. Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. *Am J Clin Nutr* 2006;84(5):1062-1069.
- Boschert S. Milk of magnesia may help ease urinary urge incontinence. *Fam Pract News* 2003;33(3):46.
- Brewer RP, Parra A, Lynch J, et al. Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. *J Neurosurg Anesthesiol* 2001;13(3):202-206.
- Carpenter TO, Delucia MC, Zhang JH, et al. A randomized controlled study of effects of dietary magnesium oxide supplementation on bone mineral content in healthy girls. *J Clin Endocrinol Metab* 2006;91(12):4866-4872.
- Cashman K, Flynn A. Optimal nutrition: calcium, magnesium and phosphorus. *Proc Nutr Soc* 1999;58:477-487.
- Clark BA, Brown RS. Unsuspected morbid hypermagnesemia in elderly patients. *Am J Nephrol* 1992;12(5):336-343.
- Classen HG. Magnesium and potassium deprivation and supplementation in animals and man: aspects in view of intestinal absorption. *Magnesium* 1984;3(4-6):257-264.
- Classen HG, Classen UG, Grimm P, et al. Pharmacokinetics of magnesium salts. *Methods Find Exp Clin Pharmacol* 1992;14(4):261-268.
- Classen HG, Marquardt P, Spath M, et al. Improvement by chlorine of the intestinal absorption of inorganic and organic Mg compounds and of their protective effect against adrenergic cardiopathy. *Recent Adv Stud Cardiac Struct Metab* 1975;6:11-19.
- Classen HG, Marquardt P, Spath M, et al. Experimental studies on the intestinal uptake of organic and inorganic magnesium and potassium compounds given alone or simultaneously. *Arzneimittelforschung* 1978;28(5):807-811.
- Classen HG, Marquardt P, Spath M, et al. Magnesium concentrations in plasma and bone following enteral administration of Br-, Cl- and Mg++ in the form of different compounds and combinations. *Arzneimittelforschung* 1976;26(2):249-253.
- Classen HG, Nowitzki S. [Clinical significance of magnesium:1: distribution in the organism, evaluation of current supply.] *Fortschr Med* 1990;108(8):148-151. [German] (Review)
- Cohen L. Potassium replacement associated with the development of tetany in a patient with hypomagnesaemia. *Magn Res* 1993;6(1):43-45.
- Cohen N, Alon I, Almozni-Sarafian D, et al. Metabolic and clinical effects of oral magnesium supplementation in furosemide-treated patients with severe congestive heart failure. *Clin Cardiol* 2000;23(6):433-436.
- Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. *Lancet* 1991;337(8744):757-760.
- Cohen JS. High-dose oral magnesium treatment of chronic, intractable erythromelalgia. *Ann Pharmacother* 2002;36(2):255-260.
- Crowther C. Is prenatal magnesium sulfate immediately prior to very preterm birth neuroprotective for babies? The ACTOMgSO4 trial: a randomized placebo-controlled trial. Abstract: LB9. Annual Meeting of the Pediatric Academic Societies. Seattle, May 4, 2003.
- Crowther CA, Hiller JE, Doyle LW, et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. *JAMA* 2003;290(20):2669-2676.
- De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. *Br J Haematol* 2000;108(2):284-289.
- de Lorges Lima M, Cruz T, Pousada JC, et al. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care* 1998;21(5):682-686.
- Deppermann KM, Lode H, Hoffken G, et al. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. *Antimicrob Agents Chemother* 1989;33(11):1901-1907.
- Devane J, Ryan MP. Evidence for a magnesium-sparing action by amiloride during renal clearance studies in rats. *Br J Pharmacol* 1983;79(4):891-896.
- Devane J, Ryan MP. Urinary magnesium excretion during amiloride administration in saline-loaded rats. *Br J Pharmacol* 1979;67(3):493P.
- Djurhuus MS, Klitgaard NA, Pedersen KK, et al. Magnesium reduces insulin-stimulated glucose uptake and serum lipid concentrations in type 1 diabetes. *Metabolism* 2001;50(12):1409-1417.

## Citations and Reference Literature: Magnesium

- Dorup I, Skajaa K, Thybo NK. [Oral magnesium supplementation to patients receiving diuretics: normalization of magnesium, potassium and sodium, and potassium pumps in the skeletal muscles.] *Ugeskr Laeger* 1994;156(27):4007-4010,4013. [Danish]
- Dorup I. Magnesium and potassium deficiency: its diagnosis, occurrence and treatment in diuretic therapy and its consequences for growth, protein synthesis and growth factors. *Acta Physiol Scand Suppl* 1994;618:1-55. (Review)
- Douban S, Brodsky MA, Whang DD, et al. Significance of magnesium in congestive heart failure. *Am Heart J* 1996;132(3):664-671. (Review)
- Duley L, Gulmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. *Cochrane Database Syst Rev* 2003;(2):CD000025. (Review)
- Durlach J, Bac P, Durlach V, et al. Magnesium status and ageing: an update. *Magnes Res* 1998;11(1):25-42. (Review)
- Durlach J, Durlach V, Bac P, et al. Magnesium and ageing: II: clinical data: aetiological mechanisms and pathophysiological consequences of magnesium deficit in the elderly. *Magnes Res* 1993;6(4):379-394. (Review)
- Ebel H, Classen HG, Marquardt P, et al. [Pharmacology and pharmacokinetics of magnesium (author's transl).] *MMW Munch Med Wochenschr* 1975;117(29-30):1243-1248. [German]
- Eichhorn EJ, Tandon PK, DiBianco R, et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. *J Am Coll Cardiol* 1993;21(3):634-640.
- Elamin A, Tuvemo T. Magnesium and insulin-dependent diabetes mellitus. *Diabetes Res Clin Pract* 1990;10(3):203-209.
- Elisaf M, Milionis H, Siamopoulos KC. Hypomagnesemic hypokalemia and hypocalcemia: clinical and laboratory characteristics. *Miner Electrolyte Metab* 1997;23(2):105-112.
- Elliott WC, Patchin DS. Effects and interactions of gentamicin, polyaspartic acid and diuretics on urine calcium concentration. *J Pharmacol Exp Ther* 1995;273(1):280-284.
- Finstad EW, Newhouse IJ, Lukaski HC, et al. The effects of magnesium supplementation on exercise performance. *Med Sci Sports Exerc* 2001;33(3):493-498.
- Friemann EFJ, Lasch H-G, Friemann S, et al. [Effect of magnesium treatment on chronic obstructive lung diseases.] *Medizinische Welt* 1991;42(4):311-315. [German]
- Fuentes JC, Salmon AA, Silver MA. Acute and chronic oral magnesium supplementation: effects on endothelial function, exercise capacity, and quality of life in patients with symptomatic heart failure. *Congest Heart Fail* 2006;12(1):9-13.
- Gaby AR. Magnesium: an inexpensive, safe, and effective treatment for cardiovascular disease. *J Adv Med* 1986;1:179-181.
- Galland LD, Baker SM, McLellan RK. Magnesium deficiency in the pathogenesis of mitral valve prolapse. *Magnesium* 1986;5(3-4):165-174.
- Galloe AM, Rasmussen HS, Jorgensen LN, et al. Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. *BMJ* 1993;307(6904):585-587.
- Galloe AM, Graudal NA. [Magnesium treatment of patients with acute myocardial infarction: ameta-analysis.] *Ugeskrift for Laeger* 1995;157(4):437-440. [Danish]
- Ganj FA, Saneifard F, Shokoohi H. The effect of magnesium hydroxide on the treatment of urinary urge incontinence: a randomized trial. Annual Scientific Meeting of the American Urogynecologic Society. Oral Poster Presentation. San Francisco, Oct 19, 2002.
- Gantz NM. Magnesium and chronic fatigue. *Lancet* 1991;338:66. (Letter)
- Garber AJ. Magnesium utilization survey in selected patients with diabetes. *Clin Ther* 1996;18(2):285-294. Erratum in *Clin Ther* 1996;18(3):559.
- Garland HO, Phipps DJ, Harpur ES. Gentamicin-induced hypercalciuria in the rat: assessment of nephron site involved. *J Pharmacol Exp Ther* 1992;263(1):293-297.
- Gaspar AZ, Gasser P, Flammer J. The influence of magnesium on visual field and peripheral vasospasm in glaucoma. *Ophthalmologica* 1995;209:11-13.
- Gilliland FD, Berhane KT, Li YF, et al. Dietary magnesium, potassium, sodium, and children's lung function. *Am J Epidemiol* 2002;155(2):125-131.
- Gordon D, Groutz A, Ascher-Landsberg J, et al. Double-blind, placebo-controlled study of magnesium hydroxide for treatment of sensory urgency and detrusor instability: preliminary results. *Br J Obstet Gynaecol* 1998;105:667-669.
- Goto K, Yasue H, Okumura K, et al. Magnesium deficiency detected by intravenous loading test in variant angina pectoris. *Am J Cardiol* 1990;65(11):709-712.
- Gottlieb SS, Baruch L, Kukin ML, et al. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. *J Am Coll Cardiol* 1990;16(4):827-831.
- Grimaldi BL. The central role of magnesium deficiency in Tourette's syndrome: causal relationships between magnesium deficiency, altered biochemical pathways and symptoms relating to Tourette's syndrome and several reported comorbid conditions. *Med Hypotheses* 2002;58(1):47-60.

## Citations and Reference Literature: Magnesium

- Grimm P, Nowitzki-Grimm S, Doerr-Kremer G, et al. In vitro magnesium absorption and the role of intestinal motility. *Methods Find Exp Clin Pharmacol* 1992;14(4):255-259.
- Guerrero-Romero F, Rodriguez-Moran M. Low serum magnesium levels and metabolic syndrome. *Acta Diabetol* 2002;39(4):209-213.
- Gupta SK, Manhas AS, Gupta VK, et al. Serum magnesium levels in idiopathic epilepsy. *J Assoc Physicians India* 1994;42(6):456-457.
- Harnett MJ, Datta S, Bhavani-Shankar K. The effect of magnesium on coagulation in parturients with preeclampsia. *Anesth Analg* 2001;92(5):1257-1260.
- He K, Liu K, Daviglus ML, et al. Magnesium intake and incidence of metabolic syndrome among young adults. *Circulation* 2006;113(13):1675-1682.
- Healy DP, Dansereau RJ, Dunn AB, et al. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. *Ann Pharmacother* 1997;12(12):1460-1464.
- Hebert P, Mehta N, Wang J, et al. Functional magnesium deficiency in critically ill patients identified using a magnesium-loading test. *Crit Care Med* 1997;25(5):749-755.
- Hinds G, Bell NP, McMaster D, et al. Normal red cell magnesium concentrations and magnesium loading tests in patients with chronic fatigue syndrome. *Ann Clin Biochem* 1994;31(Pt 5):459-461.
- Hines Burnham T, et al, ed. Drug facts and comparisons. St Louis: Facts and Comparisons; 2000.
- Holt GA. Food and drug interactions. Chicago: Precept Press; 1998.
- Howard JM, Davies S, Hunnisett A. Magnesium and chronic fatigue syndrome. *Lancet* 1992;340(8816):426.
- Hunt CD, Herbel JL, Nielsen FH. Metabolic responses of postmenopausal women to supplemental dietary boron and aluminum during usual and low magnesium intake: boron, calcium, and magnesium absorption and retention and blood mineral concentrations. *Am J Clin Nutr* 1997;65(3):803-813.
- Institute of Medicine, Food and Nutrition Board. Dietary reference intakes: calcium, phosphorus, magnesium, vitamin D and fluoride. Washington, DC: National Academy Press; 1999.
- Johansson G, Backman U, Danielson BG, et al. Effects of magnesium hydroxide in renal stone disease. *J Am Coll Nutr* 1982;1(2):179-185.
- Kavey R-EW, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation* 2006;114:2710-2738.
- Kawano Y, Matsuoka H, Takishita S, et al. Effects of magnesium supplementation in hypertensive patients. *Hypertension* 1998;32(2):260-265.
- Kelepouris E, Agus ZS. Hypomagnesemia: renal magnesium handling. *Semin Nephrol* 1998;18:58-73.
- Kelly RA, Smith TW. Recognition and management of digitalis toxicity. *Am J Cardiol* 1992;69(18):108G-119G. (Review)
- Kh R, Khullar M, Kashyap M, et al. Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. *J Hypertens* 2000;18(7):919-926.
- Kisters K, Schodjaian K, Tokmak F, et al. Effect of ethanol on blood pressure: role of magnesium. *Am J Hypertens* 2000;13:455-456 (Letter)
- Klevay LM, Milne DB. Low dietary magnesium increases supraventricular ectopy. *Am J Clin Nutr* 2002;75(3):550-554.
- Kosek JC, Mazze RI, Cousins MJ. Nephrotoxicity of gentamicin. *Lab Invest* 1974;30(1):48-57.
- Kotsaki-Kovatsi VP, Koehler-Samouilidis G, Kovatsis A, et al. Fluctuation of zinc, copper, magnesium and calcium concentrations in guinea pig tissues after administration of captopril (SQ 14225). *J Trace Elem Med Biol* 1997;11(1):32-36.
- Kurschat C, Heering P, Grabensee B. [Gitelman's syndrome: an important differential diagnosis of hypokalemia.] *Dtsch Med Wochenschr* 2003;128(22):1225-1228. [German]
- Laires MJ, Moreira H, Monteiro CP, et al. Magnesium, insulin resistance and body composition in healthy postmenopausal women. *J Am Coll Nutr* 2004;23:510S-513S.
- Langley WF, Mann D. Central nervous system magnesium deficiency. *Arch Intern Med* 1991;151(3):593-596.
- Lim D, McKay M. Food-drug interactions. *Drug Information Bull* 1995;15(2). (Review)
- Lopez-Ridaura R, Willett WC, Rimm EB, et al. Magnesium intake and risk of type 2 diabetes in men and women. *Diabetes Care* 2004;27(1):134-140.
- Lukaski HC, Nielsen FH. Dietary magnesium depletion affects metabolic responses during submaximal exercise in postmenopausal women. *J Nutr* 2002;132(5):930-935.

## Citations and Reference Literature: Magnesium

- Lukaski HC, Bolonchuk WW, Klevay LM, et al. Interactions among dietary fat, mineral status, and performance of endurance athletes: a case study. *Int J Sport Nutr Exerc Metab* 2001;11(2):186-198.
- Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. *Lancet* 2002;359(9321):1877-1890.
- Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. *Lancet* 2002;360(9341):1189-1196.
- Marier JR. Magnesium content of the food supply in the modern-day world. *Magnesium* 1986;5(1):1-8. (Review)
- Marz R. Medical nutrition from Marz. 2nd ed. Portland, OR: Omni Press; 1997. (Review)
- Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. *Clin Neurosci* 1998;5(1):24-27. (Review)
- McKee CD. Oral magnesium supplementation for diabetes and heart disease. *U S Pharmacist* 2000;25(11):79-84.
- McLean R. Magnesium and its therapeutic uses: a review. *Am J Med* 1994;96(1):63-76. (Review)
- Mehrotra R, Nolph KD, Kathuria P, et al. Hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria: a new syndrome? *Am J Kidney Dis* 1997;29(1):106-114. (Review)
- Mittendorf R, Dambrosia J, Pryde PG, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. *Am J Obstet Gynecol* 2002;186(6):1111-1118.
- Moore TJ. The role of dietary electrolytes in hypertension. *J Am Coll Nutr* 1989;8(Suppl):68S-80S.
- Moorkens G, Manuel y Keenoy B, Vertommen J, et al. Magnesium deficit in a sample of the Belgian population presenting with chronic fatigue. *Magn Res* 1997;10:329-337.
- Mousain-Bosc M, Roche M, Rapin J, et al. Magnesium vitB6 intake reduces central nervous system hyperexcitability in children. *J Am Coll Nutr* 2004;23:545S-548S.
- Muneyirci-Delale O, Dalloul M, Nacharaju VL, et al. Serum ionized magnesium and calcium and sex hormones in healthy young men: importance of serum progesterone level. *Fertil Steril* 1999;72(5):817-822.
- O'Keefe JH Jr, Harris WS, Nelson J, et al. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. *Am J Cardiol* 1995;76:480-484.
- Orchard TJ. Magnesium and type 2 diabetes mellitus. *Arch Intern Med* 1999;159(18):2119-2120.
- Oto A. Magnesium treatment in acute myocardial infarction: an unresolved consensus. *Eur Heart J* 1999;20(2):86-88. (Review)
- Owen P. Audit can ensure the safe and effective introduction of seizure prophylaxis with magnesium sulphate in obstetric practice. *Health Bull (Edinb)* 2000;58(5):414-417.
- Palmieri GM, Thompson JS, Eliel LP. Modifications of plasma magnesium by thyrocalcitonin, parathyroid extract and cortisone. *Endocrinology* 1969;84(6):1509-1511.
- Pere AK, Krogerus L, Mervaala EM, et al. Detrimental effect of dietary sodium and beneficial effect of dietary magnesium on glomerular changes in cyclosporin-A-treated spontaneously hypertensive rats. *Nephrol Dial Transplant* 1998;13(4):904-910.
- Perticone F, Borelli D, Ceravolo R, et al. Antiarrhythmic short-term protective magnesium treatment in ischemic dilated cardiomyopathy. *J Am Coll Nutr* 1990;9(5):492-499.
- Phillips PJ, Vedig AE, Jones PL, et al. Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol. *Br J Clin Pharmacol* 1980;9(5):483-491.
- Polk RE, Healy DP, Sahai J, et al. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. *Antimicrob Agents Chemother* 1989;33(11):1841-1844.
- Propst A, Propst T, Judmaier G. Comparison of the effects of ranitidine effervescent tablets and magnesium hydroxide-aluminium oxide on intragastric acidity: a single-centre, randomised, open cross-over study. *Arzneimittelforschung* 1996;46(6):621-624.
- Pronsky Z. Powers and Moore's food-medications interactions. 9th ed. Pottstown, PA: Food-Medication Interactions; 1991.
- Rasmussen HS. Clinical intervention studies on magnesium in myocardial infarction. *Magnesium* 1989;8(5-6):316-325. (Review)
- Rasmussen HS, Gronbaek M, Cinton C, et al. One-year death rate in 270 patients with suspected acute myocardial infarction, initially treated with intravenous magnesium or placebo. *Clin Cardiol* 1988;11(6):377-381.
- Redwood SR, Taggart PI, Sutton PM, et al. Effect of magnesium on the monophasic action potential during early ischemia in the in vivo human heart. *J Am Coll Cardiol* 1996;28(7):1765-1769.
- Reunanen A, Knekt P, Marniemi J, et al. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. *Eur J Clin Nutr* 1996;50(7):431-437.
- Riss P, Bartl W, Jelincic D. Clinical aspects and treatment of calf muscle cramps during pregnancy. *Geburtshilfe Frauenheilkd* 1983;43(5):329-331.

## Citations and Reference Literature: Magnesium

- Rissanen TH, Voutilainen S, Virtanen JK, et al. Low intake of fruits, berries and vegetables is associated with excess mortality in men: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. *J Nutr* 2003;133(1):199-204.
- Rob PM. [Magnesium deficiency after kidney transplantation and cyclosporine therapy.] *Fortschr Med* 1996;114(10):125-126. [German]
- Rob PM, Lebeau A, Nobiling R, et al. Magnesium metabolism: basic aspects and implications of cyclosporine toxicity in rats. *Nephron* 1996;72(1):59-66.
- Robinson C, Weigly E. Basic nutrition and diet therapy. New York: MacMillan; 1984.
- Roe DA. Diet and drug interactions. New York: Van Nostrand Reinhold; 1989.
- Roe DA. Drug-induced nutritional deficiencies. 2nd ed. Westport, CT: Avi Publishing; 1985.
- Roe DA. Risk factors in drug-induced nutritional deficiencies. In: Roe DA, Campbell T, eds. *Drugs and nutrients: the interactive effects*. New York: Marcel Dekker; 1984:505-523.
- Romano TJ. Magnesium deficiency in systemic lupus erythematosus. *J Nutr Environ Med* 1997;7:107-111.
- Romano TJ, Stiller JW. Magnesium deficiency in fibromyalgia syndrome. *J Nutr Med* 1994;4:165-167.
- Rosanoff A, Seelig MS. Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. *J Am Coll Nutr* 2004;23:501S-505S.
- Rowe BH, Camargo CA Jr. Multicenter Airway Research Collaboration (MARC) investigators: the use of magnesium sulfate in acute asthma: rapid uptake of evidence in North American emergency departments. *J Allergy Clin Immunol* 2006;117(1):53-58.
- Rude RK. Magnesium metabolism and deficiency. *Endocrinol Metab Clin North Am* 1993;22(2):377-395. (Review)
- Ryan MP. Interrelationships of magnesium and potassium homeostasis. *Miner Electrolyte Metab* 1993;19(4-5):290-295.
- Ryder KM, Shorr RI, Bush AJ, et al. Magnesium intake from food and supplements is associated with bone mineral density in healthy older white subjects. *J Am Geriatr Soc* 2005;53(11):1875-1880.
- Sabatier M, Arnaud MJ, Kastenmayer P, et al. Meal effect on magnesium bioavailability from mineral water in healthy women. *Am J Clin Nutr* 2002;75(1):65-71.
- Saris NE, Mervaala E, Karppanen H, et al. Magnesium: an update on physiological, clinical and analytical aspects. *Clin Chim Acta* 2000;294(1-2):1-26. (Review)
- Sasaki S, Oshima T, Matsuura H, et al. Abnormal magnesium status in patients with cardiovascular diseases. *Clin Sci (Lond)* 2000;98(2):175-181.
- Shechter M, Hod H, Rabinowitz B, et al. Long-term outcome in thrombolysis-ineligible acute myocardial infarction patients treated with intravenous magnesium sulfate. Heart Institute, Sheba Medical Center and Tel Aviv University, Tel Hashomer, Israel. *Circulation* 2001;104(No 17, Suppl II):II-744-745. (Abstract No 3515)
- Shuck P, Bohmer K, Resch KL. [Migraine and prevention of migraine: the value of magnesium.] *Schweiz Med Wochenschr* 1999;129(3):63-70. [German] (Review)
- Schultes G. [High doses of magnesium in the treatment of angina pectoris.] *Fortschritte der Medizin* 1991;109(35): 81. [German]
- Schumann K, Classen HG, Hages M, et al. Bioavailability of oral vitamins, minerals, and trace elements in perspective. *Arzneimittelforschung* 1997;47(4):369-380. (Review)
- Schwanstecher M, Loser S, Rietze I, et al. Phosphate and thiophosphate group donating adenine and guanine nucleotides inhibit glibenclamide binding to membranes from pancreatic islets. *Naunyn Schmiedeberg's Arch Pharmacol* 1991;343(1):83-89.
- Seelig M. Cardiovascular consequences of magnesium deficiency and loss: pathogenesis, prevalence and manifestations: magnesium and chloride loss in refractory potassium repletion. *Am J Cardiol* 1989;63(14):4G-21G. (Review)
- Seelig MS. Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). *J Am Coll Nutr* 1994;13(5):429-446. (Review)
- Shaheen BE, Cornish LA. Magnesium in the treatment of acute myocardial infarction. *Clin Pharm* 1993;12(8):588-596. (Review)
- Shechter M, Merz CN, Paul-Labrador M, et al. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. *Am J Cardiol* 1999;84(2):152-156.
- Skotnicki AB, Jablonski MJ, Musial J, et al. The role of magnesium in the pathogenesis and therapy of bronchial asthma. *Przegl Lek* 1997;54(9):630-633.
- Soliman HM, Mercan D, Lobo SS, et al. Development of ionized hypomagnesemia is associated with higher mortality rates. *Crit Care Med* 2003;31(4):1082-1087.
- Song Y, Manson JE, Buring JE, et al. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. *Diabetes Care* 2004;27(1):59-65.
- Sueta CA, Patterson JH, Adams KF Jr. Antiarrhythmic action of pharmacological administration of magnesium in heart failure: a critical review of new data. *Magn Res* 1995;8(4):389-401.

## Citations and Reference Literature: Magnesium

- Suzuki T, Koizumi J, Moroji T, et al. Effects of long-term anticonvulsant therapy on copper, zinc, and magnesium in hair and serum of epileptics. *Biol Psychiatry* 1992;31(6):571-581.
- Tam M, Gomez S, Gonzalez-Gross M, et al. Possible roles of magnesium on the immune system. *Eur J Clin Nutr* 2003;57(10):1193-1197. (Review)
- Taubert K, Keil G. [Pilot study on the use of magnesium in the treatment of migraine and stress headache.] *Zeitschrift fur Arztliche Fortbildung* 1991;85(1-2):67-68. [German]
- Teixeira F, Geraldies CF, Gil VM, et al. In vitro complexation of aluminum and magnesium by cimetidine and ranitidine: anuclear magnetic resonance study. *Gastroenterol Clin Biol* 1984;8(11):879-880. (Letter)
- Teo KK, Yusuf S. Role of magnesium in reducing mortality in acute myocardial infarction: a review of the evidence. *Drugs* 1993;46(3):347-359. (Review)
- Third National Health and Nutrition Examination Survey (NHANES III). 1988-94 NHANES III Dietary Supplement Information Data File Documentation. Series 11, No. 2A. April 1998.
- Threlkeld DS, ed. Systemic anti-infectives, fluoroquinolones. In: *Facts and comparisons drug information*. St Louis: Facts and Comparisons;1994:340n-340o.
- Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. *Am Fam Physician* 1991;44(5):1651-1658. (Review)
- Tucker KL, Hannan MT, Chen H, et al. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. *Am J Clin Nutr* 1999;69(4):727-736.
- USDA. Composition of foods: USDA handbook #8. Washington, DC:ARS, USDA;1976-1986.
- van Dam RM, Feskens EJM. Coffee consumption and risk of type 2 diabetes mellitus. *Lancet* 2002;360:1477-1478.
- Wang F, Van Den Eeden SK, Ackerson LM, et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. *Headache* 2003;43(6):601-610.
- Weaver K. Magnesium and its role in vascular reactivity and coagulation. *Contemp Nutr* 1987;12(3):1.
- Weaver K. Magnesium and migraine. *Headache* 1990;30(3):168.
- Weberg R, Berstad A, Aaseth J, et al. Mineral-metabolic side effects of low-dose antacids. *Scand J Gastroenterol* 1985;20(6):741-746.
- Werbach MR. *Foundations of nutritional medicine*. Tarzana, CA: Third Line Press; 1997. (Review)
- Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. *Altern Med Rev* 2000;5(2):93-108.
- Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. *JAMA* 2006;296:2947-2953.
- Yokota K, Kato M, Lister F, et al. Clinical efficacy of magnesium supplementation in patients with type 2 diabetes. *J Am Coll Nutr* 2004;23:506S-509S.
- Young IS, Goh EM, McKillop UH, et al. Magnesium status and digoxin toxicity. *Br J Clin Pharmacol* 1991;32(6):717-721.